The substantial reduction in the price target from $17 to $5, while maintaining a Buy rating, suggests that while HC Wainwright & Co. remains optimistic about Apollomics' long-term prospects, there may be short-term challenges or adjustments in valuation that could negatively impact the stock price in the short term.